Angiotensin II and COVID-19. Secrets of interactions
The article describes current data on the relationship of renin-angiotensin system and related drugs with the risk of COVID-19 infection and its outcomes. Analysis of the latest publications did not reveal association of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with any risk of an unfavorable outcomes, and there was no data for withdrawal of these drugs..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Российский кардиологический журнал - 25(2020), 4 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
A. O. Konradi [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Angiotensin converting enzyme 2 |
|---|
| doi: |
10.15829/1560-4071-2020-3861 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ030682746 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ030682746 | ||
| 003 | DE-627 | ||
| 005 | 20230410123325.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2020 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.15829/1560-4071-2020-3861 |2 doi | |
| 035 | |a (DE-627)DOAJ030682746 | ||
| 035 | |a (DE-599)DOAJ46ee347d699f49cabad07d16092d7e04 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 050 | 0 | |a RC666-701 | |
| 100 | 0 | |a A. O. Konradi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Angiotensin II and COVID-19. Secrets of interactions |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The article describes current data on the relationship of renin-angiotensin system and related drugs with the risk of COVID-19 infection and its outcomes. Analysis of the latest publications did not reveal association of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with any risk of an unfavorable outcomes, and there was no data for withdrawal of these drugs. | ||
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a angiotensin converting enzyme inhibitors | |
| 650 | 4 | |a angiotensin converting enzyme 2 | |
| 653 | 0 | |a Diseases of the circulatory (Cardiovascular) system | |
| 700 | 0 | |a A. O. Nedoshivin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Российский кардиологический журнал |d «FIRMA «SILICEA» LLC, 2019 |g 25(2020), 4 |w (DE-627)DOAJ000120294 |x 26187620 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2020 |g number:4 |
| 856 | 4 | 0 | |u https://doi.org/10.15829/1560-4071-2020-3861 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/46ee347d699f49cabad07d16092d7e04 |z kostenfrei |
| 856 | 4 | 0 | |u https://russjcardiol.elpub.ru/jour/article/view/3861 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1560-4071 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2618-7620 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2020 |e 4 | ||